Repligen (NASDAQ:RGEN) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Repligen (NASDAQ:RGEN) posted its earnings results on Tuesday. The biotechnology company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.07, Zacks reports. The firm had revenue of $209.31 million for the quarter, compared to analysts’ expectations of $206.71 million. During the same period last year, the firm earned $0.46 earnings per share. Repligen’s revenue for the quarter was up 10.9% compared to the same quarter last year.

Here are the key takeaways from Repligen’s conference call:

• Repligen reported record third-quarter revenue of $209 million, up 12.5% organically, while adjusted operating margin expanded 170 basis points to 15.9%. Management raised 2026 revenue guidance to $844 million-$852 million and adjusted EPS guidance to $2.05-$2.09.
• The BioLife acquisition closed on October 6 and is expected to contribute approximately $24 million of fourth-quarter revenue. Repligen said it has already captured more than half of anticipated year-one operating expense synergies and expects at least $0.05 of 2027 earnings accretion.
• Capital-equipment orders rose at a mid-teens rate and reached their highest quarterly level in five years, creating a stronger backlog entering 2027. Consumables grew 20% and services grew more than 20%, with systems under service contracts up nearly 40% year to date.
• Filtration revenue declined 11% in the quarter due to ATF and gene-therapy headwinds, the Polymem divestiture, and customer-requested delivery timing; management expects the franchise to be flat to slightly down for 2026. Executives said decision-making remains slow and the equipment “tap” has not yet fully opened, despite a strong funnel.
• Chromatography grew more than 50%, Proteins more than 40%, and Analytics 20% in the quarter, prompting higher full-year growth expectations for Chromatography and Analytics of at least 30%. China revenue increased more than 40%, while management said BioLife and expanding cell-therapy, biosimilar, and Asia-Pacific opportunities support reported growth of at least 25% in 2027 and revenue above $1 billion.

Repligen Stock Up 4.1%

NASDAQ RGEN traded up $7.29 during midday trading on Wednesday, hitting $183.09. The company had a trading volume of 84,280 shares, compared to its average volume of 1,048,700. The stock has a market cap of $10.33 billion, a price-to-earnings ratio of 250.80 and a beta of 1.08. The firm has a fifty day simple moving average of $177.50 and a two-hundred day simple moving average of $144.99. Repligen has a fifty-two week low of $100.99 and a fifty-two week high of $198.87.

Key Repligen News

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen reported third-quarter revenue of $209.3 million, up 10.9% year over year and above the roughly $206.7 million consensus estimate. Adjusted EPS of $0.53 also exceeded expectations of $0.46. Repligen Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management raised full-year 2026 revenue guidance to $844 million-$852 million, representing approximately 14.5%-15.5% reported growth. The company also completed its BioLife acquisition, expanding its cell-therapy offerings and potentially accelerating long-term growth. Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
• Positive Sentiment: Some commentary characterized the revenue outlook as a potential catalyst and argued that RGEN could be undervalued if its growth and cash-flow expansion continue. Repligen Could Be 12% Undervalued
• Neutral Sentiment: Valuation remains a key debate. With a very high earnings multiple, one analysis viewed the stock as fairly valued because expected cash-flow growth is already reflected in the share price. Repligen Stock Looks Fairly Valued
• Negative Sentiment: Repligen recorded a $41.2 million impairment charge, causing reported quarterly profit to turn into a loss. Although the charge is noncash, it weakens GAAP results and may prompt investors to focus more heavily on adjusted figures. Repligen Takes $41.2 Million Impairment Charge
• Negative Sentiment: The Filtration segment remained weak, and management said some expected system deliveries moved into 2027. That delay creates near-term uncertainty despite strength in Proteins, Chromatography, and Analytics, likely explaining the market’s negative reaction to otherwise solid results. Repligen Slips as Investors Weigh Filtration Weakness

Wall Street Analyst Weigh In

RGEN has been the subject of several research reports. UBS Group reaffirmed a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Evercore reiterated an “outperform” rating and issued a $160.00 price target on shares of Repligen in a report on Monday, July 6th. Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. Finally, Zacks Research lowered shares of Repligen from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $175.71.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.